[PPARgamma agonists against respiratory syncytial virus infection in vitro study].

Abstract

OBJECTIVE:

To search the effect of PPARgamma agonists for infection of RSV in vitro.

METHODS:

The CPE of Hep-2 and A549 cells induced by RSV infection were observed. The effects of 15d-PGJ2 and rosiglitazone on change of CPE of A549 cells induced by RSV infection for 48 h were observed, too. MTT assay was used to detect the rate of viral suppression, and the protective effects of 15d-PGJ2 and rosiglitazone on A549 cells induced by RSV infection for 48 h.

RESULTS:

A549 cells interfered by 15d-PGJ2 (5 -25 micromol/L) and rosiglitazone (10-50 micromol/L) did not show obvious CPE, MTT assay also showed that the survival rate of A549 cells induced by RSV infection with PPARgamma agonists added, was significantly higher than that of RSV infection without PPARgamma agonists added, the difference was statistically significant (P < 0.01), but comparision between the two drugs showed no statistical significance. The optimal concentrations of 15d-PGJ2 and rosiglitazone were 5 micromol/L and 10 micromol/L respectively.

CONCLUSIONS:

PPARgamma agonist can reduce the CPE of A549 cells after RSV infection and improve the survival rate of A549 cells. PPARgamma agonist can counteract the infection of RSV in A549 cells.

• Authors: Chun-Jie Wan, Lin Dong, Jie Lin, Xiao-Fang Chen
• Journal: Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology (Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi) Vol. 25 Issue 6 Pg. 480-2 (Dec 2011) ISSN: 1003-9279 [Print] China
• PMID: 22734242 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 15-deoxyprostaglandin J2
• PPAR gamma
• Thiazolidinediones
• Rosiglitazone
• Prostaglandin D2

Topics

• Cells, Cultured
• Humans
• PPAR gamma (agonists)
• Prostaglandin D2 (analogs & derivatives, pharmacology)
• Respiratory Syncytial Viruses (drug effects)
• Rosiglitazone
• Thiazolidinediones (pharmacology)